Emergent BioSolutions Snags $1.25B Contract to Provide Anthrax Vaccine to Feds
Rockville, MD-based Emergent Biosolutions (NYSE: EBS) today announced it has landed a contract worth $1.25 billion over five years to provide the federal government with 44.75 million doses of BioThrax, the only vaccine licensed by the U.S. Food and Drug Administration to protect against anthrax infection. The company will manufacture the vaccine at its facility in Lansing, MI.
In 2006, former Michigan Governor Jennifer Granholm announced state and local tax credits valued at more than $15 million in support of a proposed 50,000-square-foot expansion project at the Lansing facility. Emergent also has a Seattle R&D operation, which it obtained last year through its acquisition of Trubion Pharmaceuticals.